Effectdossier · gearchiveerd kwartaal
IRWD
Ironwood Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
17Gevolgde houders
0Δ houders
58.02MGehouden aandelen
$76.00MGerapporteerde waarde
+0Nieuwe posities
−0Uitstappen
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -4.4% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 88 | -4 | 110.50M | $465.13M | +4 | −8 |
| Q1 2026 | 94 | +9 | 125.58M | $394.14M | +11 | −2 |
| Q4 2025 | 85 | +2 | 100.81M | $339.86M | +2 | — |
| Q3 2025 | 17 | 0 | 58.02M | $76.00M | — | — |
| Q2 2025 | 14 | 0 | 58.90M | $42.25M | +1 | −1 |
| Q1 2025 | 11 | 0 | 30.28M | $44.51M | +1 | −1 |
| Q4 2024 | 11 | 0 | 26.27M | $116.38M | +1 | −1 |
| Q3 2024 | 10 | -2 | 15.74M | $64.83M | — | −2 |
| Q2 2024 | 12 | — | 17.55M | $114.44M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 16.07M | -0.8% | $21.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passief) | 16.07M | -0.8% | $21.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passief) | 16.07M | -0.8% | $21.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passief) | 16.07M | -0.8% | $21.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | BlackRock ✦ (passief) | 12.06M | +0.3% | $15.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 8.35M | -0.6% | $10.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 5.38M | -12.8% | $7.05M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 5.38M | -12.8% | $7.05M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 5.38M | -12.8% | $7.05M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 5.38M | -12.8% | $7.05M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 5.38M | -12.8% | $7.05M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Geode Capital Management ✦ (passief) | 3.61M | +3.3% | $4.74M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Geode Capital Management ✦ (passief) | 3.61M | +3.3% | $4.74M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | State Street Global Advisors ✦ (passief) | 3.16M | +1.6% | $4.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | Marshall Wace ✦ | 3.14M | -21.3% | $4.12M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Marshall Wace ✦ | 3.14M | -21.3% | $4.12M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 25 | Two Sigma Investments ✦ | 2.53M | -7.9% | $3.32M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 26 | Goldman Sachs Group ✦ | 1.08M | — | $1.42M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Goldman Sachs Group ✦ | 1.08M | — | $1.42M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Citadel Advisors ✦ | 644.05K | +108.2% | $843,701 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 29 | Citadel Advisors ✦ | 644.05K | +108.2% | $843,701 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 30 | Fidelity (FMR) ✦ | 559.95K | +12.6% | $733,530 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 31 | Fidelity (FMR) ✦ | 559.95K | +12.6% | $733,530 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 32 | Morgan Stanley ✦ | 477.10K | — | $625,001 | 0.0% | n/c | 1 | SEC ↗ |
| 33 | Morgan Stanley ✦ | 477.10K | — | $625,001 | 0.0% | n/c | 1 | SEC ↗ |
| 34 | Morgan Stanley ✦ | 477.10K | — | $625,001 | 0.0% | n/c | 1 | SEC ↗ |
| 35 | Morgan Stanley ✦ | 477.10K | — | $625,001 | 0.0% | n/c | 1 | SEC ↗ |
| 36 | Morgan Stanley ✦ | 477.10K | — | $625,001 | 0.0% | n/c | 1 | SEC ↗ |
| 37 | Morgan Stanley ✦ | 477.10K | — | $625,001 | 0.0% | n/c | 1 | SEC ↗ |
| 38 | D. E. Shaw & Co. ✦ | 372.27K | -77.7% | $487,674 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 39 | D. E. Shaw & Co. ✦ | 372.27K | -77.7% | $487,674 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 40 | Millennium Management ✦ | 250.12K | +159.6% | $327,656 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 224.31K | — | $293,852 | 0.0% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 224.31K | — | $293,852 | 0.0% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 224.31K | — | $293,852 | 0.0% | n/c | 1 | SEC ↗ |
| 44 | JPMorgan Chase ✦ | 224.31K | — | $293,852 | 0.0% | n/c | 1 | SEC ↗ |
| 45 | JPMorgan Chase ✦ | 224.31K | — | $293,852 | 0.0% | n/c | 1 | SEC ↗ |
| 46 | JPMorgan Chase ✦ | 224.31K | — | $293,852 | 0.0% | n/c | 1 | SEC ↗ |
| 47 | T. Rowe Price ✦ | 80.18K | -53.5% | $106,000 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 48 | Fisher Asset Management ✦ | 10.00K | 0.0% | $13,100 | 0.0% | Held | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 222 houders, 159.91M aandelen, $533.78M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API